Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid)

Adverse event—serious 16 to 60 weeks · people with asthma

Subcutaneous omalizumab + steroid probably leads to lower adverse event—serious 16 to 60 weeks compared with placebo + steroid (stable steroid) (moderate certainty).

1 finding from 1 review

Omalizumab for asthma in adults and children 2014 · Cochrane Headline outcomes only
OR 0.72 [0.57, 0.91]
15 studies · 5713 participants
Moderate